6/22/2026

Janusmed kön och genus

Janusmed kön och genus – Cenobamat

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Cenobamat

Cenobamat

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Christian CA, Reddy DS, Maguire J, Forcelli PA. Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies. Pharmacol Rev. 2020;72(4):767-800.

  2. Reddy DS, Thompson W, Calderara G . Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett. 2021;750:135753.

  3. McHugh JC, Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol. 2008;83:11-26.

  4. Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007;76(1):60-5.

  5. Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia. 2005;46(6):956-60.

  6. Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2005;39(3):956-60.

  7. Ontozry (cenobamate). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-04-23, cited 2026-03-24]

  8. Food and Drug Administration (FDA). Prescribing information - XCOPRI (cenobamate). DailyMed [www]. [cited 2026-03-24].

  9. Operto FF, Izzo V, Assenza G, et al. Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study. Front Pharmacol. 2025;16:1668382.

  10. Charlier B, Izzo V, Assenza G, et al. Do Cenobamate Pharmacokinetics Change with Co-Administered Antiseizure Medications? An Exploratory Analysis of Responder Patients with Focal Drug-Resistant Epilepsy. Pharmaceutics. 2026;18(1):92.

  11. Food and Drug Administration (FDA). Statistical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2018-02-15, cited 2026-03-24].

  12. Czapińska-Ciepiela E, Kondak A, Kowalczyk M, et al. Early antiseizure response to cenobamate (200 mg/day) in focal drug-resistant epilepsy: a retrospective single-center analysis. Epilepsy Behav Rep. 2025;32:100839.

  13. Strzelczyk A, von Podewils F, Hamer HM, et al. Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study. CNS Drugs. 2025;39(3):321-331.

  14. Winter Y, Dargham RA, Ellwardt E, et al. Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. Epilepsy Behav. 2026;175:110835.

  15. Food and Drug Administration (FDA). Clinical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2019-10-15, cited 2026-03-24].

  16. Iwamoto BK, Whitaker AM, Agurs LD, et al. Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations. J Child Neurol. 2026;41(3):336-344.

  17. Hashem J, Ade S, Ivanier S, et al. Cenobamate-associated weight loss (Cenobaweight study). Cenobamate-associated weight loss (Cenobaweight study). 2025.

  18. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]

  1. Christian CA, Reddy DS, Maguire J, Forcelli PA. Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies. Pharmacol Rev. 2020;72(4):767-800.
  2. Reddy DS, Thompson W, Calderara G . Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis. Neurosci Lett. 2021;750:135753.
  3. McHugh JC, Delanty N. Epidemiology and classification of epilepsy: gender comparisons. Int Rev Neurobiol. 2008;83:11-26.
  4. Christensen J, Vestergaard M, Pedersen MG, Pedersen CB, Olsen J, Sidenius P. Incidence and prevalence of epilepsy in Denmark. Epilepsy Res. 2007;76(1):60-5.
  5. Christensen J, Kjeldsen MJ, Andersen H, Friis ML, Sidenius P. Gender differences in epilepsy. Epilepsia. 2005;46(6):956-60.
  6. Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci. 2005;39(3):956-60.
  7. Ontozry (cenobamate). Summary of Product Characteristics. European Medicines Agency (EMA) [updated 2024-04-23, cited 2026-03-24]
  8. Food and Drug Administration (FDA). Prescribing information - XCOPRI (cenobamate). DailyMed [www]. [cited 2026-03-24].
  9. Operto FF, Izzo V, Assenza G, et al. Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study. Front Pharmacol. 2025;16:1668382.
  10. Charlier B, Izzo V, Assenza G, et al. Do Cenobamate Pharmacokinetics Change with Co-Administered Antiseizure Medications? An Exploratory Analysis of Responder Patients with Focal Drug-Resistant Epilepsy. Pharmaceutics. 2026;18(1):92.
  11. Food and Drug Administration (FDA). Statistical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2018-02-15, cited 2026-03-24].
  12. Czapińska-Ciepiela E, Kondak A, Kowalczyk M, et al. Early antiseizure response to cenobamate (200 mg/day) in focal drug-resistant epilepsy: a retrospective single-center analysis. Epilepsy Behav Rep. 2025;32:100839.
  13. Strzelczyk A, von Podewils F, Hamer HM, et al. Post-marketing Experience with Cenobamate in the Treatment of Focal Epilepsies: A Multicentre Cohort Study. CNS Drugs. 2025;39(3):321-331.
  14. Winter Y, Dargham RA, Ellwardt E, et al. Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. Epilepsy Behav. 2026;175:110835.
  15. Food and Drug Administration (FDA). Clinical review - XCOPRI (cenobamate). Drugs@FDA [www]. [updated 2019-10-15, cited 2026-03-24].
  16. Iwamoto BK, Whitaker AM, Agurs LD, et al. Effects of Cenobamate in Pediatric Epilepsy: Demographic Considerations. J Child Neurol. 2026;41(3):336-344.
  17. Hashem J, Ade S, Ivanier S, et al. Cenobamate-associated weight loss (Cenobaweight study). Cenobamate-associated weight loss (Cenobaweight study). 2025.
  18. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2025 [cited 2026-03-20.]